ストックスクリーナーアプリを入手
3.9605
8.84%
-0.4495
Quantum Biopharma Ltd (QNTM) 最新ニュース
Quantum BioPharma submits IND application for MS drug candidate By Investing.com - Investing.com Australia
Quantum BioPharma Submits Investigational New Drug (IND) Application to United States Food and Drug Administration (FDA) for Lucid-MS Phase Two Clinical Trial in Multiple Sclerosis - markets.businessinsider.com
Quantum BioPharma (QNTM) Files FDA Application for New MS Drug - GuruFocus
Quantum BioPharma Files FDA IND for Phase 2 Trial of Lucid-MS in Multiple Sclerosis - TipRanks
Quantum BioPharma submits investigational new drug (IND) application to United States Food and Drug Administration (FDA) - MarketScreener
Quantum BioPharma submits IND application for MS drug candidate - Investing.com
Quantum BioPharma (QNTM) advances Lucid-MS with FDA IND for Phase 2 MS trial - Stock Titan
Quantum BioPharma pushes MS drug toward Phase 2 with FDA filing - Stock Titan
Top Cannabis Stocks To Keep An Eye OnMarch 31st - marketbeat.com
Quantum BioPharma (QNTM) Plans Phase 2 Trial for Multiple Sclero - GuruFocus
Quantum BioPharma (QNTM) Partners with Allucent for Lucid-MS Pha - GuruFocus
Quantum BioPharma (QNTM) Plans Phase 2 Trial for Multiple Sclerosis Treatment - gurufocus.com
Quantum BioPharma signs binding letter of intent with Allucent to conduct Phase 2 clinical trial in Multiple Sclerosis - MarketScreener
Quantum BioPharma Taps Allucent for Phase 2 Trial of Novel MS Drug Lucid-MS - tipranks.com
Quantum BioPharma And Allucent Enter Binding Letter Of Intent For Phase 2 Clinical Trial In Multiple Sclerosis - MarketScreener
Quantum BioPharma partners with Allucent for MS drug trial By Investing.com - Investing.com Australia
Quantum BioPharma Partners with Allucent to Advance Phase 2 Clinical Trial of Lucid-MS for Multiple Sclerosis Treatment - Quiver Quantitative
Quantum BioPharma (QNTM) lines up Allucent for Lucid-MS Phase 2 trial - Stock Titan
New MS treatment targeting demyelination moves toward Phase 2 - Stock Titan
Portfolio Recap: Will Quantum BioPharma Ltd stock benefit from M A2026 Breakouts & Breakdowns & Safe Capital Growth Plans - baoquankhu1.vn
Quantum BioPharma Raises C$3.75 Million and Converts Debt in Capital Restructuring Push - TipRanks
Institution Moves: Will Quantum BioPharma Ltd outperform during market rallies - baoquankhu1.vn
Promising Cannabis Stocks To Add to Your WatchlistMarch 28th - MarketBeat
Can Quantum BioPharma Ltd generate free cash flow2026 Sector Review & Technical Pattern Based Buy Signals - baoquankhu1.vn
Quantum Biopharma Provides Corporate Update - Sahm
Quantum BioPharma Posts Strong 2025 Results, Extends Cash Runway and Advances MS and Alcohol Health Programs - TipRanks
Top Cannabis Stocks To Watch TodayMarch 27th - marketbeat.com
Quantum BioPharma reports $11.3M cash, runway to January 2028 By Investing.com - Investing.com Canada
Quantum Biopharma Maintains No Going Concern Status in Audited Financial Results for Fiscal Year 2025 - geneonline.com
Quantum BioPharma reports $11.3M cash, runway to January 2028 - Investing.com
Quantum BioPharma Ltd. Completes Phase 1 Trial for MS Drug Lucid-21-302 and Publishes unbuzzd™ Clinical Trial Results - Quiver Quantitative
Quantum Biopharma’s 2025 Audited Year End Financial Results Maintain ‘No Going Concern’ Status - MarketScreener
[6-K] Quantum Biopharma Ltd. Current Report (Foreign Issuer) | QNTM SEC FilingForm 6-K - Stock Titan
Quantum BioPharma names principal investigator for MS trial By Investing.com - Investing.com Australia
Quantum BioPharma (FRA:0K91) NonCurrent Deferred Revenue : €0.00 Mil (As of Sep. 2025) - GuruFocus
Quantum Biopharma Ltd. Subordinate Voting Shares Class B Balance Sheet – HAM:0K91 - TradingView
Quantum Biopharma Ltd. Subordinate Voting Shares Class B - TradingView
Quantum Biopharma's 2025 Audited Year End Financial Results Maintain 'No Going Concern' Status - bitget.com
Quantum BioPharma Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Quantum BioPharma (Nasdaq: QNTM) outlines 2025 drug-development and IP risks - Stock Titan
Diluted earnings per share (diluted EPS) of Quantum Biopharma Ltd. Subordinate Voting Shares Class B – HAM:0K91 - TradingView
Cannabis Stocks To ResearchMarch 26th - marketbeat.com
Quantum BioPharma Taps MS Expert to Lead Phase 2 Trial of Lucid-MS - TipRanks
Quantum BioPharma announces appointment of principal investigator for planned phase 2 clinical trial of Lucid-21-302 (Lucid-MS) in multiple sclerosis - MarketScreener
Quantum Biopharma Announces Appointment of Principal Investigator for Planned Phase 2 Clinical Trial of Lucid-21-302 (Lucid-MS) in Multiple Sclerosis - The Manila Times
Quantum BioPharma (QNTM) advances Lucid-MS plan, details unbuzzd™ royalties and tax assets - Stock Titan
Quantum Biopharma Announces Appointment of Principal - GlobeNewswire
Best Cannabis Stocks To Watch NowMarch 25th - marketbeat.com
Market Outlook: Should I hold or sell Quantum BioPharma Ltd now2026 Setups & Risk Controlled Swing Trade Alerts - baoquankhu1.vn
Cannabis Stocks To Add to Your WatchlistMarch 24th - marketbeat.com
Quantum BioPharma publishes study on alcohol supplement unbuzzd By Investing.com - Investing.com Australia
Quantum Biopharma Ltd. Announces Peer-Reviewed Publication of Clinical Trial Results for Unbuzzd - MarketScreener
Quantum BioPharma publishes study on alcohol supplement unbuzzd - Investing.com
Quantum BioPharma Wins Peer-Reviewed Validation for Unbuzzd Alcohol-Relief Supplement - TipRanks
Quantum BioPharma announces peer-reviewed journal publication of groundbreaking clinical trial with Unbuzzd - marketscreener.com
Quantum BioPharma Ltd. Publishes Positive Clinical Trial Results for Dietary Supplement 'Unbuzzd' in World Journal of Pharmaceutical and Medical Research - Moomoo
Quantum BioPharma Ltd. Publishes Positive Clinical Trial Results for Dietary Supplement 'unbuzzd' in World Journal of Pharmaceutical and Medical Research - Quiver Quantitative
Quantum BioPharma Announces Peer-Reviewed Journal Publication of Groundbreaking Clinical Trial With Unbuzzd - GlobeNewswire
1.34%
0.05%
大文字化:
|
ボリューム (24 時間):